Prognostic factors in breast cancer with extracranial oligometastases and the appropriate role of radiation therapy.
10.3857/roj.2015.33.4.301
- Author:
Gyu Sang YOO
1
;
Jeong Il YU
;
Won PARK
;
Seung Jae HUH
;
Doo Ho CHOI
Author Information
1. Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. doho.choi@samsung.com
- Publication Type:Original Article
- Keywords:
Oligometastasis;
Radiotherapy;
Breast neoplasms
- MeSH:
Brain;
Breast Neoplasms*;
Breast*;
Disease Progression;
Disease-Free Survival;
Humans;
Lymph Nodes;
Medical Records;
Neoplasm Metastasis;
Radiotherapy;
Retrospective Studies
- From:Radiation Oncology Journal
2015;33(4):301-309
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: To identify prognostic factors for disease progression and survival of patients with extracranial oligometastatic breast cancer (EOMBC), and to investigate the role of radiation therapy (RT) for metastatic lesions. MATERIALS AND METHODS: We retrospectively reviewed the medical records of 50 patients who had been diagnosed with EOMBC following standard treatment for primary breast cancer initially, and received RT for metastatic lesions, with or without other systemic therapy between January 2004 and December 2008. EOMBC was defined as breast cancer with five or less metastases involving any organs except the brain. All patients had bone metastasis (BM) and seven patients had pulmonary, hepatic, or lymph node metastasis. Median RT dose applied to metastatic lesions was 30 Gy (range, 20 to 60 Gy). RESULTS: The 5-year tumor local control (LC) and 3-year distant progression-free survival (DPFS) rate were 66.1% and 36.8%, respectively. High RT dose (> or =50 Gy10) was significantly associated with improved LC. The 5-year overall survival (OS) rate was 49%. Positive hormone receptor status, pathologic nodal stage of primary cancer, solitary BM, and whole-lesion RT (WLRT), defined as RT whose field encompassed entire extent of disease, were associated with better survival. On analysis for subgroup of solitary BM, high RT dose was significantly associated with improved LC and DPFS, shorter metastasis-to-RT interval (< or =1 month) with improved DPFS, and WLRT with improved DPFS and OS, respectively. CONCLUSION: High-dose RT in solitary BM status and WLRT have the potential to improve the progression-free survival and OS of patients with EOMBC.
